IDBS has unveiled what it describes as significant new capabilities to E-WorkBook, its enterprise data management platform, with major enhancements to the web client and integrations with IDBS workflow and analytics engine
IDBS has added a new functionality to its ChemBook electronic laboratory notebook (ELN)
IDBS has launched Omics Workbench, a new web-based product that supports Next Generation Sequencing (NGS) and other omics techniques in research and clinical labs
IDBS has launched the IDBS Biomarker Discovery and Validation Solution, which streamlines biomarker research and improves collaboration, intellectual property management, and scientific understanding of complex disease, leading to new therapies
IDBS has released E-WorkBook Suite 8.2, the latest version of its ELN that captures and stores both contextual and experimental fact data in a searchable, secure, traceable and compliant environment
IDBS has released InforSense Suite 5.1, the latest version of its scientific business intelligence solution, incorporating data integration, analysis and visualisation
From pharmaceuticals to energy, healthcare to consumer goods, IDBS helps research and development (R&D) teams make discoveries that have the potential to transform the lives of populations worldwide.
We are passionate about optimizing scientific process and making data genuinely useful and actionable. As a leading global provider of advanced software for R&D, we provide organizations with the technology they need to securely capture, manage, share and exploit structured and unstructured data.
IDBS has released E-WorkBook Suite 7.1. It is a compliant, secure and extensible electronic laboratory notebook (ELN) designed for research scientists of any discipline.
IDBS has released the latest version of its E-WorkBook Suite - the compliant, secure and extensible Electronic Lab Notebook (ELN) designed for research scientists of any discipline.
IDBS has launched ActivityBase Xtended Edition (ActivityBase XE) v7.0, with improved drug screening capabilites. The new release includes support for complex assay types (e.g. multiplexing and HCS).
Elsevier and ExactCure recently announced a collaboration to develop and offer to hospitals – without charge – drug-specific exposure models for 20 already approved medicines that are being tested as potential treatments for Covid-19.
With the world’s focus on the COVID-19 pandemic, LIMS providers are working to develop solutions tailored to assist in the testing and management of virus samples.
Researchers at Harvard Medical School (HMS) have released an open source drug discovery platform, VirtualFlow, that harnesses supercomputing power to screen potentially billions of small organic compound structures in parallel, in the hunt for promising new drug molecules.
When designing a component or system, where do you start? In days gone by, designers would literally go back to the drawing board, using their experience and expertise to develop a new concept.
Effective utilisation of computing tools is critical to both AI and HPC research, with recent projects in both fields highlighting the scientific benefit of carefully managing resources.
Advances in computer vision combined with AI computing are helping pathologists to more accurately identify subtypes of cancer - leading to better treatments for patients, explains Dan Ruderman.
